Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026 Phase 3 protocol of roxadustat for the treatment of anemia in
SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further
In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo Similar rates of TI for patients treated with roxadustat were observed in